Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study

Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Oppermann U, Chiabudini M, von Weikersthal LF, Budweiser S, Nacke A, Taeuscher D, Welslau M, Potthoff K. .

Int J Cancer. 2023 Jul 1;153(1):141-152. doi: 10.1002/ijc.34467. Epub 2023 Mar 8.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: / Journal: International Journal of Cancer

NEPTUN
2023
The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice

Martens UM, Schröder J, Bengsch F, Sellmann L, Busies S, Frank-Gleich S, Zaiss M, Decker T, Schneeweiss A, Schuler M, Grebhardt S, Zacharias S, Marschner N, Kasenda B, Potthoff K, Vannier C.

BMC Cancer. 2023 Jun 13;23(1):543. doi: 10.1186/s12885-023-11046-3

Link

Download

Indikation: Präzisionsonkologie, Precision Oncology / Veranstaltung: / Journal: BMC Cancer
INFINITY
2023
Tucatinib in patients with locally advanced or metastatic HER2-positive breast cancer who received at least two prior anti-HER2 treatment regimens: Study design of the non-interventional study TRACE in Germany and Austria

N. Harbeck , R. Bartsch , V. Müller , M. Balic , D. Egle , E. Schumacher-Wulf , M. Angerer , A. Nusch , C. Uleer , M. Welslau , J. Radosa , D. Wrobel , R. de Buhr , M. Glasstetter , J. Hanselmann , C. Hogrefe , N. Marschner ,K. Gratzke , A. Welt

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal:
TRACE
2023
Genetic alterations with potential impact on PD-(L)1 targeted treatment in various cancer entities – Biobank research project of the INFINITY registry

Hillebrand LE, Vannier C, Jermann PM , Matter M, Läubli H, Grebhardt S, Wright PR, Woerner SM, Kansenda B, Marschner N, Potthoff K.

Download

Indikation: Präzisionsonkologie, Precision Oncology / Veranstaltung: DGP / Journal:
INFINITY
2023
The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice.

Martens UM, Schröder J, Bengsch F, Sellmann L, Busies S, Frank-Gleich S, Zaiss M, Decker T, Schneeweiss A, Schuler M, Grebhardt S, Zacharias S, Marschner N, Kasenda B, Potthoff K, Vannier C.

BMC Cancer. 2023 Jun 13;23(1):543. doi: 10.1186/s12885-023-11046-3.

Indikation: Präzisionsonkologie, Precision Oncology / Veranstaltung: - / Journal: BMC Cancer
INFINITY
2023
Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.

Thill M, Zahn MO, Welt A, Stickeler E, Nusch A, Fietz T, Rauh J, Wetzel N, Kruggel L, Jänicke M, Marschner N, Harbeck N, Wöckel A, Decker T; OPAL study group.

Breast Cancer Res Treat. 2023 Apr;198(3):545-553. doi: 10.1007/s10549-023-06882-7. Epub 2023 Feb 18. PMID: 36807725; PMCID: PMC10036409.

Link

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Cancer Research and Treatment
OPAL
2023
Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL

Thill M, Zahn MO, Welt A, Stickeler E, Nusch A, Fietz T, Rauh J, Wetzel N, Kruggel L, Jänicke M, Marschner N, Harbeck N, Wöckel A, Decker T; OPAL study group.

Breast Cancer Res Treat. 2023 Apr;198(3):545-553. doi: 10.1007/s10549-023-06882-7. Epub 2023 Feb 18. PMID: 36807725; PMCID: PMC10036409.

Link

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: / Journal: Breast Cancer Research and Treatment
OPAL
2023
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

Metzenmacher M, Griesinger F, Hummel HD, Elender C, Schäfer H, de Wit M, Kaiser U, Kern J, Jänicke M, Spring L, Zacharias S, Kaiser-Osterhues A, Groth A, Hipper A, Zaun G, Dörfel S, Güldenzoph B, Müller L, Uhlig J, Thomas M, Sebastian M, Eberhardt WEE; CRISP Registry Group.

Eur Respir J. 2023 Feb 2;61(2):2201336. doi: 10.1183/13993003.01336-2022.

Link

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: / Journal: European Respiratory Journal
CRISP
2023
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world

Marschner N, Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach SH, Kreher S, Wolf T, Binninger A, Chiabudini M, Kaiser-Osterhues A, Jänicke M; TPK-Group (Tumour Registry Pancreatic Cancer).

Int J Cancer. 2023 Feb 1;152(3):458-469. doi: 10.1002/ijc.34271. Epub 2022 Sep 22

Link

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: / Journal: International Journal of Cancer
TPK
2023
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry.

Metzenmacher M, Griesinger F, Hummel HD, Elender C, Schäfer H, de Wit M, Kaiser U, Kern J, Jänicke M, Spring L, Zacharias S, Kaiser-Osterhues A, Groth A, Hipper A, Zaun G, Dörfel S, Güldenzoph B, Müller L, Uhlig J, Thomas M, Sebastian M, Eberhardt WEE; CRISP Registry Group.

Eur Respir J. 2023 Feb 2;61(2):2201336. doi: 10.1183/13993003.01336-2022.

Link

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: European Respiratory Journal
CRISP
2023